---
title: "Spruce Biosciences Appoints Daven Mody and Bruno Gagnon to Executive Leadership Team"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274660154.md"
datetime: "2026-02-03T13:02:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274660154.md)
  - [en](https://longbridge.com/en/news/274660154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274660154.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274660154.md) | [English](https://longbridge.com/en/news/274660154.md)


# Spruce Biosciences Appoints Daven Mody and Bruno Gagnon to Executive Leadership Team

Spruce Biosciences Inc. has announced the appointments of Daven Mody, Pharm.D., as Senior Vice President of Regulatory and Quality, and Bruno Gagnon, B.Pharm., M.Sc., as Senior Vice President, Clinical Development Operations. Mody brings extensive experience in regulatory filings and approvals, while Gagnon has more than 30 years of experience in leading clinical operations for global drug development programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203184321) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Spruce Biosciences (SPRB.US)](https://longbridge.com/zh-HK/quote/SPRB.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)

## 相關資訊與研究

- [Spruce Biosciences 10-K: $0.0M Revenue, $(50.83) EPS on $(39.0) M Net Loss](https://longbridge.com/zh-HK/news/278384128.md)
- [Spruce Biosciences 2025 net loss narrows, secures $50 mln funding](https://longbridge.com/zh-HK/news/278380208.md)
- [EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market](https://longbridge.com/zh-HK/news/278715508.md)
- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/zh-HK/news/278542482.md)
- [Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy](https://longbridge.com/zh-HK/news/278644625.md)